Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?

التفاصيل البيبلوغرافية
العنوان:	Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
المؤلفون:	Matej Samoš, Tomáš Bolek, Lucia Stančiaková, Martin Jozef Péč, Kristína Brisudová, Ingrid Škorňová, Ján Staško, Marián Mokáň, Peter Kubisz
المصدر:	Journal of Clinical Medicine; Volume 11; Issue 21; Pages: 6369
بيانات النشر:	Multidisciplinary Digital Publishing Institute
سنة النشر:	2022
المجموعة:	MDPI Open Access Publishing
مصطلحات موضوعية:	direct oral anticoagulants, tailored medicine, DOAC laboratory monitoring, atrial fibrillation, adverse thrombotic and hemorrhagic events
الوصف:	Direct oral anticoagulants (DOAC) are currently the drug of choice for drug prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). However, repeated ischemic stroke or systemic embolism and bleeding while on DOAC is still a challenging clinical phenomenon in the management of future long-term anticoagulation. It is not known whether tailoring the DOAC therapy to achieve optimal therapeutic drug levels could improve the clinical course of DOAC therapy. To be able to tailor the therapy, it is necessary to have a valid laboratory method for DOAC level assessment, to be aware of factors influencing DOAC levels and to have clinical options to tailor the treatment. Furthermore, the data regarding clinical efficacy/safety of tailored DOAC regimes are still lacking. This article reviews the current data on tailored direct oral anticoagulation in patients with AF.
نوع الوثيقة:	text
وصف الملف:	application/pdf
اللغة:	English
Relation:	Vascular Medicine; https://dx.doi.org/10.3390/jcm11216369
DOI:	10.3390/jcm11216369
الاتاحة:	https://doi.org/10.3390/jcm11216369
Rights:	https://creativecommons.org/licenses/by/4.0/
رقم الانضمام:	edsbas.3E73B345
قاعدة البيانات:	BASE

View record in BASE

كن أول من يترك تعليقا!